Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px
Document › Details

Arix Bioscience plc. (12/11/18). "Press Release: Arix Appoints Dr Christian Schetter as Entrepreneur In Residence (EIR)". London.

Organisations Organisation Arix Bioscience plc (LSE: ARIX)
  Today Arix Bioscience (Group)
  Group Arix Bioscience (Group)
  Organisation 2 Rigontec GmbH
  Group Merck (US) (MSD) (Group)
Products Product venture capital
  Product 2 BIOTECH
  Index term 2 Rigontec–Merck (US): investment, 201709– acquisition €115m cash upfront + €349m milestones
Persons Person Schetter, Christian (Arix Bioscience 201812– Entrepreneur In Residence before Rigontec + Fresenius Biotech + Coley GmbH)
  Person 2 Anderson, Joe (Arix Bioscience 201809– Chief Investment Officer before CEO before Abingworth)
     


Experienced industry executive joins investment team to support portfolio development


Arix Bioscience plc (LSE:ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation, today announces the appointment of Dr Christian Schetter as Entrepreneur in Residence (EIR). Christian has over 20 years’ industry experience across the life sciences sector, and joins Arix from German immuno-oncology company Rigontec GmbH, where he was CEO for four years before its acquisition by MSD.

Joe Anderson, Chief Investment Officer of Arix said: “I am delighted to welcome Christian to the team. He has a track record of creating companies that foster exciting science and securing impressive exits. His extensive experience of building companies in the life science industry will greatly benefit Arix as we continue to build on our existing investments and leverage our extensive pipeline.”

Christian Schetter commented: “Arix has a varied portfolio of innovative companies that it is committed to building and developing. Arix has grown significantly since its IPO and not only built a diverse portfolio, but also a unique group of industry and academic partners, and a talented international investment team. I am very excited to join Arix and look forward to supporting the team in evolving this pipeline as we build the next generation of world leading biotech companies.”

Dr Schetter has over 20 years’ experience in the life science industry. In 2017, as CEO of Rigontec GmbH, he led the company to a successful acquisition by MSD valued at EUR 115m with an additional EUR 349m in potential milestone payments. Prior to his role at Rigontec GmbH, Christian was President and CEO of Neovii Biotech (previously Fresenius Biotech). During his tenure, one antibody product was brought to market and the indication for another product expanded. Christian was also instrumental in selling Fresenius Biotech to the Neopharm Group, Israel, to form Neovii Biotech and positioning it as a successful standalone business. He was SVP of European Operations at Coley Pharmaceutical Group and Managing Director of Coley GmbH. Christian was part of the leadership team which built Coley Pharmaceuticals from inception through multiple financing rounds, a NASDAQ IPO and, following several significant pharma deals, to a trade sale to Pfizer in 2007.

Before entering the life science industry, Christian was successfully performing academic research at the Max Planck Institute in Martinsried, Germany. He received his undergraduate degree and PhD from the University of Cologne and did postdoctoral research in oncology and virology at the Scripps Research Institute in La Jolla, California.

ENDS


Enquiries

For more information on Arix, please contact:

Arix Bioscience plc
Charlotte Parry, Head of Investor Relations
+44 (0)20 7290 1072
charlotte@arixbioscience.com

Optimum Strategic Communications
Mary Clark, Supriya Mathur
+44 (0) 203 950 9144
optimum.arix@optimumcomms.com

Burns McClellan (US Media & IR Enquiries)
Nancie Steinberg, Bill Slattery Jr.
+1 212-213-0006
arix@burnsmc.com


About Arix Bioscience plc

Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange.

   
Record changed: 2018-12-19

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for Arix Bioscience (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top